Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Influenza

Influenza Vaccination Cuts Risk of Critical Illness in Children

Brian Park, PharmD

January 26, 2022

During a season predominated by 2 vaccine-mismatched viruses, vaccination was estimated to reduce the risk of life-threatening influenza illness by 75%.

Clinicians can use tips from the ACAAI to help patients manage their allergy symptoms.

Allergies

Ryaltris Nasal Spray Approved for Seasonal Allergic Rhinitis

Brian Park, PharmD

January 24, 2022

Ryaltris is a metered, fixed-dose nasal spray that delivers 665mcg of olopatadine hydrochloride and 25mcg of mometasone furoate in each spray.

Lung Cancer

Patritumab Deruxtecan Gets Breakthrough Tx Status for Metastatic EGFR-Mutated NSCLC

Brian Park, PharmD

January 4, 2022

Patritumab deruxtecan consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.

General Medicine

ASPR Pauses Distribution of Certain Monoclonal Antibodies for COVID-19

Brian Park, PharmD

December 30, 2021

Circulating SARS-CoV-2 viral variants, including Omicron, may be associated with resistance to bamlanivimab and etesevimab together or REGEN-COV.

General Medicine

Early Data Show Evusheld Retains Neutralizing Activity Against Omicron

Brian Park, PharmD

December 28, 2021

The FDA study shows that the neutralizing potency of the antibody combination was within the range of neutralizing titers found in an individual previously infected with COVID-19.

Asthma

Tezspire Approved as Add-On Maintenance Treatment for Severe Asthma

Brian Park, PharmD

December 22, 2021

Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.

Critical Care

Final Results Confirm Paxlovid Reduces COVID-19 Related Hospitalization, Death

Brian Park, PharmD

December 16, 2021

Paxlovid consists of PF-07321332, which inhibits the viral replication of SARS-CoV-2 by blocking the activity of the SARS-CoV-2-3CL protease, and low-dose ritonavir.

General Medicine

Longer-Term Data: Pfizer-BioNTech COVID-19 Vaccine Highly Effective in Adolescents

Brian Park, PharmD

November 29, 2021

Findings from data collected between November 2020 and September 2021 showed that among 2228 participants, the vaccine was 100% effective.

Influenza

Multidose Vial Presentation of Audenz, an H5N1 Influenza Vaccine, Approved

Brian Park, PharmD

November 29, 2021

Audenz is an inactivated cell-based influenza vaccine that contains MF59, a proprietary adjuvant.

General Medicine

Long-Acting Antibody Combo Reduced Risk of Symptomatic COVID-19 in Phase 3 Trials

Brian Park, PharmD

November 23, 2021

AZD7442 is a combination of 2 long-acting monoclonal antibodies, tixagevimab and cilgavimab, derived from B-cells donated by convalescent patients who were infected with the SARS-CoV-2 virus.

Next post in General Medicine